Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

177Lu-RAD202

Radiopharmaceutical · Kills target cells, directed at HER2 (ERBB2) · developed by Radiopharm Theranostics

Early Phase 1 Most advanced trial
RADX Developer
1 Registered trials

What is 177Lu-RAD202?

177Lu-RAD202 is a lutetium-177 radiopharmaceutical given at treatment doses. It is studied in advanced solid tumors with HER2 gene mutation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Radiopharmaceutical
Targets
HER2 (ERBB2) (biomarker)
Mechanism
Kills target cells, directed at HER2 (ERBB2)
Therapy area
Oncology
Developer
Radiopharm Theranostics, Ltd (RADX)
FDA status
Investigational, not approved in the US. Most advanced trial: Early Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06824155 Early Phase 1 HER2 Gene Mutation Recruiting RADX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorsHER2 Gene Mutation

Other drugs acting on ERBB2

More from Radiopharm Theranostics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the RADX page.

Follow RADX, the company behind 177Lu-RAD202

See RADX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RADX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.